Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Sunday.

TBPH has been the subject of a number of other research reports. HC Wainwright raised their price target on shares of Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. B. Riley began coverage on Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $24.25.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $18.50 on Friday. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $18.96. The company has a market cap of $937.40 million, a PE ratio of 32.46 and a beta of 0.07. The business has a 50-day simple moving average of $15.05 and a two-hundred day simple moving average of $12.71.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently modified their holdings of TBPH. Quarry LP acquired a new stake in Theravance Biopharma during the third quarter worth about $26,000. Caitong International Asset Management Co. Ltd boosted its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Theravance Biopharma during the 3rd quarter valued at approximately $101,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.